Versartis Inc. (NASDAQ:VSAR)’s share price traded up 1.6% during mid-day trading on Wednesday . The company traded as high as $13.15 and last traded at $13.10, with a volume of 67,972 shares. The stock had previously closed at $12.90.

A number of equities analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Versartis from a “hold” rating to a “sell” rating in a report on Wednesday, June 8th. Morgan Stanley reaffirmed a “hold” rating on shares of Versartis in a report on Saturday, April 30th. Credit Suisse Group AG reaffirmed a “sell” rating and set a $9.00 price objective on shares of Versartis in a report on Friday, July 29th. Citigroup Inc. set a $23.00 price objective on shares of Versartis and gave the stock a “buy” rating in a report on Thursday, August 11th. Finally, Canaccord Genuity set a $28.00 price objective on shares of Versartis and gave the stock a “buy” rating in a report on Thursday, August 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $18.00.

The firm has a 50-day moving average price of $11.20 and a 200 day moving average price of $9.33. The company’s market cap is $385.81 million.

Versartis (NASDAQ:VSAR) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.03. On average, analysts predict that Versartis Inc. will post ($2.76) earnings per share for the current fiscal year.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.